

Invex Therapeutics Ltd

(ACN 632 145 334)

APPENDIX 4D – HALF-YEAR FINANCIAL REPORT

Reporting period

Current period: Half year ended 31 December 2021

Previous corresponding period: Half year ended 31 December 2020

Results for announcement to market

	% increase/ (decrease)	31 December 2021	31 December 2020
Other income	94.3%	222,556	114,549
Loss from ordinary activities after tax attributable to members	70.5%	1,795,869	1,056,048
Net loss for the period attributable to members	70.5%	1,795,869	1,056,048

Dividends

No dividends have been declared or paid during the period ended 31 December 2021. The Directors do not recommend the payment of a dividend in respect of the period ended 31 December 2021.

The Group does not have any dividend reinvestment plan in operation.

Explanation of results

Please refer to Results and Review of Operations within the Directors' Report for an explanation of the results.

Net tangible assets per security

Net tangible asset per share	31 December 2021 cents per share	30 June 2021 cents per share
Net tangible asset per share	0.41	0.43

Other

The Group has not gained or lost control of any other entities during the period.

There are no associates or joint ventures held by the Group.

Review Conclusion

This Report is based on the Half year financial report for the period ended 31 December 2021. The financial report has been subject to a review by an independent auditor and the review is not subject to a qualification.



HALF YEAR FINANCIAL REPORT

for the half year ended 31 December 2021

Invex Therapeutics Ltd
Half Year Report 31 December 2021

CONTENTS

CORPORATE INFORMATION.....	3
DIRECTORS' REPORT	4
AUDITOR'S INDEPENDENCE DECLARATION	7
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION	9
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	10
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS	11
NOTES TO THE FINANCIAL STATEMENTS	12
DIRECTORS' DECLARATION.....	17
INDEPENDENT AUDITOR'S REVIEW REPORT	18

Invex Therapeutics Ltd
Half Year Report 31 December 2021

CORPORATE INFORMATION

Directors

Prof. Alexandra Sinclair	Executive Director
Dr Thomas Duthy	Executive Director
Dr Jason Loveridge	Non-Executive Chairman
David McAuliffe	Non-Executive Director
Dr Megan Baldwin	Non-Executive Director

Company Secretary

Narelle Warren

Registered and principal administrative office

Level 1, 38 Rowland Street
Subiaco WA 6008
Telephone: +61 8 9382 0137

Share Registry

Automic Registry Services
Level 5
126 Phillip Street
Sydney NSW 2000

Solicitors

Steinepreis Paganin
Level 1
Milligan Street
Perth WA 6000

Bankers

Westpac Banking Corporation
Level 14
109 St Georges Terrace
Perth WA 6000

Auditors

BDO Audit (WA) Pty Ltd
Level 9
Mia Yellagonga Tower 2
5 Spring Street
Perth WA 6000

Securities Exchange Listing

Invex Therapeutics Ltd is listed on the Australian Securities Exchange (ASX Code: IXC)

Invex Therapeutics Ltd

Half Year Report 31 December 2021

DIRECTORS' REPORT

Your Directors have pleasure in submitting their report together with the condensed consolidated financial statements of Invex Therapeutics Ltd (**Invex** or **Group**) and its controlled entity (**Invex UK**) for the half year ended 31 December 2021. In order to comply with the provisions of the Corporations Act 2001, the Directors' report as follows:

DIRECTORS

The Directors in office at any time during the period and until the date of this report are as follows:

Professor Alexandra Sinclair	Executive Director
Dr Thomas Duthy	Executive Director
Dr Jason Loveridge	Non-Executive Chairman
Mr David McAuliffe	Non-Executive Independent Director
Dr Megan Baldwin	Non-Executive Independent Director

The Directors have been in office since the start of the period to the date of this report unless otherwise stated.

PRINCIPAL ACTIVITIES

Invex is a biopharmaceutical Group focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP). The Group's primary focus is Idiopathic Intracranial Hypertension (IIH), a severe condition of predominately overweight women of childbearing age, which can lead to disabling headaches and in some patients, permanent vision loss. The Group's lead program is the development of Presendin™ for IIH. Presendin™ is a once per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010). Invex completed a Phase II trial in 2020 and proceeded to plan and prepare to commence a single, Phase III clinical trial ("IIH EVOLVE") designed to meet the requirements for market approval of Presendin™ for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia. Presendin™ is the Group's filed (and granted) trademark name for reformulated Exenatide.

The principal activity of the Group during the period has been to plan and prepare to commence the Phase III IIH EVOLVE clinical trial.

RESULTS

The net loss attributable to members of the Group for the half year ended 31 December 2021 was \$1,795,869 (31 December 2020: \$1,056,048). This loss included share-based payments, costs associated with planning for the Phase III clinical trial, manufacturing drug and the compliance and administration costs of an ASX listed company. The Group's cash at bank was \$31.37 million at 31 December 2021.

REVIEW OF OPERATIONS

Operational Highlights

For the half year ended 31 December 2021, the Group is pleased to report the following major achievements:

- In August, the Company was granted a European patent, number EP3188747, which was subsequently published on 8 September 2021. The patent covers the use of GLP-1 receptor agonists, including Exenatide, in reducing elevated ICP associated with IIH and will provide patent protection until at least August 2035.

DIRECTORS' REPORT (CONT'D)

REVIEW OF OPERATIONS (CONT'D)

- In September, Invex announced the signing of an exclusive long-term Collaboration and Manufacturing Agreement with Peptron, Inc. a biopharmaceutical company developing sustained-release peptide-based medicines based in Daejeon, Korea. Under the terms of the agreement, Peptron will provide Invex with access to its intellectual property, including an extensive preclinical and clinical data package, and GMP grade Presendin™ for all of its clinical trials in idiopathic intracranial hypertension as well as for commercial use, once Presendin™ is approved. The agreement provides a defined price per dose for the global supply of Presendin™ for clinical studies and for the first ten years following the first commercial sale. In addition, Invex has granted Peptron an exclusive license to commercialise Presendin™ for IIH in Korea.
- In November, Invex announced the finalisation of its regulatory and clinical trial strategy for Presendin™ in IIH. The completion of this strategy was an important milestone for the Company after significant scientific and regulatory consultation. The single Phase III clinical trial has been designed to meet the requirements for market approval of Presendin™ for the treatment of IIH in the EU, UK and Australia (IIH EVOLVE). The trial plans to enrol 240 newly diagnosed IIH patients who will be randomised to receive either once weekly subcutaneous injections of Presendin™ or placebo across 37 centres in Europe, UK, Australia and the United States (US). Outcomes from the IIH EVOLVE clinical trial are expected to facilitate future discussions with the US Food and Drug Administration (FDA) regarding registration of Presendin™ in the US in the future.
- In December, the Company announced Professor Michael Wall, MD had been appointed as the Trial Steering Group Chairperson for the IIH EVOLVE Phase III clinical trial. Professor Wall is a Professor of Ophthalmology and Neurology at the University of Iowa College of Medicine and Director of the Iowa Visual Field Reading Center. He is considered a global key opinion leader in IIH, having made a significant contribution to the clinical and scientific literature pertaining to the diagnosis, treatment and management of this disease and has led a significant number of important IIH clinical trials.
- In addition, in line with previous market guidance, Invex successfully filed the first Clinical Trial Application to commence the IIH-EVOLVE trial in Australia, through an application to a specific Human Research Ethics Committee (HREC). In Australia, HRECs are required under the Therapeutic Goods Act to review and monitor all clinical trials of unregistered drugs. If successful, HREC clearance will allow Invex to commence recruitment of IIH patients under the parameters of the approved trial protocol.

COVID-19

The COVID-19 pandemic and rolling government shutdowns did impact moderately on Invex's development timeline. In particular, the pandemic has affected the Group's ability to hold in-person negotiations with the Company's manufacturing partner Peptron Inc. and limited travel for Company consultants and staff. The Company was able to largely mitigate these impacts through virtual meeting platforms.

Outlook

The Group continues with the necessary preparative work for the IIH-EVOLVE study, including regulatory submissions, documentation and filings to facilitate the importation and release of Presendin™ into countries where the study will take place, and centre selection. Patient recruitment for the Phase III registration trial for Presendin™ is anticipated to commence across multiple jurisdictions during 2022.

SIGNIFICANT CHANGES IN STATE OF AFFAIRS

There have been no significant changes in the state of affairs of the Group during the financial period not otherwise disclosed in this report or the financial statements.

DIRECTORS' REPORT (CONT'D)

AFTER BALANCE DATE EVENTS

The impact of the Coronavirus (COVID-19) pandemic is ongoing with a new Omicron variant circulating widely throughout Australia and the rest of world, including the UK during the financial period. It is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation continues to evolve and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

In January 2022, the Company announced that Professor Alexandra Sinclair had entered into an employment agreement with the Company's UK subsidiary, Invex Therapeutics Ltd, effective 1 March 2022. In addition, the Company entered into a new consultancy agreement with Non-Executive Chairman Dr Jason Loveridge, effective 1 February 2022.

There have been, no other matters or circumstances have arisen since the end of the period which significantly affected or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Company in subsequent financial years.

LIKELY DEVELOPMENTS

Other than as disclosed elsewhere in this report, there are no likely developments in the operations of the Group that were not finalised at the date of this report.

ENVIRONMENTAL REGULATION

The Group is not subject to any significant environmental Commonwealth or State regulations or laws.


DIVIDENDS

There were no dividends paid or declared or recommended since the start of the period.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report.

Signed in accordance with a resolution of the Directors.



David McAuliffe
Non-Executive Director
22 February 2022

DECLARATION OF INDEPENDENCE BY JARRAD PRUE TO THE DIRECTORS OF INVEX THERAPEUTICS LTD

As lead auditor for the review of Invex Therapeutics Ltd for the half-year ended 31 December 2021, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Invex Therapeutics Ltd and the entity it controlled during the period.

A handwritten signature in black ink, appearing to read 'J Prue', is written over a light grey horizontal line.

Jarrad Prue
Director

BDO Audit (WA) Pty Ltd
Perth, 22 February 2022

Invex Therapeutics Ltd
Half Year Report 31 December 2021

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the half year ended 31 December 2021

	Note	31 December 2021 \$	31 December 2020 \$
Other income	3	222,556	114,549
Research and development expenses		(1,113,941)	(548,266)
Manufacturing expenses		(140,825)	-
Administration and corporate costs		(498,322)	(341,965)
Share based payments	4	(265,337)	(280,366)
Loss before income tax		(1,795,869)	(1,056,048)
Income tax benefit/(expense)		-	-
Loss after tax for the period attributable to the members of Invex Therapeutics Ltd		(1,795,869)	(1,056,048)
Items that may be reclassified subsequently to profit or loss:			
Exchange differences on translation of foreign operations, net of tax		(7,849)	(2,185)
Total comprehensive loss for the period attributable to the members of Invex Therapeutics Ltd		(1,803,718)	(1,058,233)
Basic and diluted loss per share (cents per share) for the period attributed to the members of Invex Therapeutics Ltd		(2.37)	(1.41)

The above Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income is to be read in conjunction with the accompanying notes.

Invex Therapeutics Ltd
Half Year Report 31 December 2021

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2021

	Note	31 December 2021 \$	30 June 2021 \$
ASSETS			
Current Assets			
Cash and cash equivalents		31,366,041	32,716,091
Other receivables		144,939	21,199
Total Current Assets		31,510,980	32,737,290
TOTAL ASSETS		31,510,980	32,737,290
LIABILITIES			
Current Liabilities			
Trade and other payables	5	966,001	658,614
Total Current Liabilities		966,001	658,614
TOTAL LIABILITIES		966,001	658,614
NET ASSETS		30,544,979	32,078,676
EQUITY			
Issued capital	6	36,413,432	36,413,432
Reserves	7	1,803,728	1,541,556
Accumulated losses		(7,672,181)	(5,876,312)
TOTAL EQUITY		30,544,979	32,078,676

The above Condensed Consolidated Statement of Financial Position is to be read in conjunction with the accompanying notes.

Invex Therapeutics Ltd
Half Year Report 31 December 2021

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the half year ended 31 December 2021

	Issued Capital	Reserves	Accumulated Losses	Total
	\$	\$	\$	\$
Balance at 1 July 2020	27,017,127	977,242	(3,592,401)	24,401,968
Loss for the period	-	-	(1,056,048)	(1,056,048)
Fx reserve movements	-	(2,185)	-	(2,185)
Total comprehensive loss for the period	-	(2,185)	(1,056,048)	(1,058,233)
Share- based payments reserve	-	280,366	-	280,366
Transaction with owners, directly recorded in equity:				
Issue of share capital, net of transaction costs (Refer Note 6)	9,396,305	-	-	9,396,305
Balance at 31 December 2020	36,413,432	1,255,423	(4,648,449)	33,020,406
Balance at 1 July 2021	36,413,432	1,541,556	(5,876,312)	32,078,676
Loss for the period	-	-	(1,795,869)	(1,795,869)
Fx reserve movements	-	(3,165)	-	(3,165)
Total comprehensive loss for the period	-	(3,165)	(1,795,869)	(1,803,718)
Share-based payment reserve	-	265,337	-	265,337
Issue of share capital, net of transaction costs	-	-	-	-
Balance at 31 December 2021	36,413,432	1,803,728	(7,672,181)	(30,544,979)

The above Condensed Consolidated Statement of Changes in Equity is to be read in conjunction with the accompanying notes.

Invex Therapeutics Ltd
Half Year Report 31 December 2021

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the half year ended 31 December 2021

	31 December 2021 \$	31 December 2020 \$
Cash flows from operating activities		
Payments to suppliers and employees	(1,572,606)	(927,097)
R&D Tax rebate received	184,068	-
Interest received	38,488	114,549
Net cash flows used in operating activities	(1,350,050)	(812,548)
Cash flows from financing activities		
Subscription proceeds from ordinary shares	-	8,647,547
Payments for capital raising costs	-	(553,670)
Net cash flows provided by financing activities	-	8,093,877
Net increase/(decrease) in cash and cash equivalents	(1,350,050)	7,281,329
Cash and cash equivalents at beginning period	32,716,091	26,300,459
Cash and cash equivalents at period end	31,366,041	33,581,788

The above Condensed Consolidated Statement of Cash Flows is to be read in conjunction with the accompanying notes.

Invex Therapeutics Ltd
Half Year Report 31 December 2021

NOTES TO THE FINANCIAL STATEMENTS

For the half year ended 31 December 2021

NOTE 1: BASIS OF PREPARATION OF THE HALF YEAR FINANCIAL REPORT

Invex Therapeutics Ltd (**Invex** or **Company**) is a listed public company incorporated and domiciled in Australia and is the parent Company. The consolidated interim financial report of the Company as at and for the six months ended 31 December 2021 comprises the Company and its subsidiary (together referred to as the "Group").

A description of the nature of the Group's operations and its principal activities is included in the Directors' Report which does not form part of this financial report.

The condensed consolidated financial statements were authorised by the Board of Directors on the date of signing the Directors' Declaration.

a) Basis of Preparation

The half year financial statements are general purpose financial statements prepared in accordance with Australian Accounting Standards 134 'Interim Financial Reporting' and the Corporations Act 2001.

The half year report does not include full disclosures of the type normally included in an annual financial report. For the purposes of preparing the half year condensed financial statements, the half year has been treated as a discrete reporting period.

It is recommended that this financial report be read in conjunction with the annual financial report for the period ended 30 June 2021 and any public announcements made by Invex Therapeutics Ltd during the half year in accordance with continuous disclosure requirements arising under the Corporations Act 2001.

Invex Therapeutics Ltd is a company Ltd by shares. The financial report is presented in Australian currency and all amounts noted are in Australian dollars unless otherwise noted. Invex Therapeutics is a for profit entity.

Apart from as disclosed at c) the accounting policies have been consistently applied by the consolidated entity and are consistent with those applied in the previous financial period.

b) Adoption of new and revised accounting standards

These condensed consolidated financial statements have been prepared using the same accounting policies as used in the annual financial statements for the period ended 30 June 2021, except for the impact of the new and amended standards and interpretations issued by the AASB.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (**AASB**) that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

c) Changes to critical accounting estimates and judgements

The preparation of the Group's condensed consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of asset or liabilities affected in future periods.

The critical accounting estimates and judgements adopted in the half year financial report are consistent with those applied in the preparation of the Group's annual report for the period ended 30 June 2021.

Invex Therapeutics Ltd
Half Year Report 31 December 2021

NOTES TO THE FINANCIAL STATEMENTS

For the half year ended 31 December 2021

NOTE 2: SEGMENT REPORTING

The chief operating decision maker has been identified as the Board of Directors.

The Company has one operating segment being clinical drug development that is consistent with internal reporting provided to the chief operating decision maker. The chief operating decision maker has been identified as the Board of Directors.

In the half year ended 31 December 2021 the Group operated in one segment only.

NOTE 3: OTHER INCOME

	31 December 2021 \$	31 December 2020 \$
Interest and other income		
R&D Tax rebate	184,068	-
Interest revenue	38,488	114,549
	222,556	114,549

NOTE 4: SHARE-BASED PAYMENTS

Share-based payments made during the period ended 31 December 2021 are summarised below.

(a) Recognised Share-based Payment Expense

	31 December 2021 \$	31 December 2020 \$
Options granted to Adviser for services	-	82,398
Forfeiture of Adviser options	-	(114,626)
Options granted to Directors and Employees as incentive	265,337	312,594
	265,337	280,366

(b) Options granted to Directors and Employees for services

The Company's current Employee Share Incentive Plan (**Incentive Plan**) was approved by shareholders on 25 November 2021 and updates the previous Plan under which the current unlisted options on issue were granted to Employees and Directors. The Incentive Plan is designed to provide medium and long term incentives for all employees (including non-executive and executive directors) and to attract and retain experienced employees, board members and executive officers and provide motivation to make the Company more successful. Performance securities issued to Directors are subject to shareholder approval.

Under the Plan, participants may be granted incentive securities which only vest if certain milestones are met. Participation in the Plan is at the Board's discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefit.

Any incentive security may only be granted or exercised after the incentive security has vested and other conditions imposed by the Board have been satisfied. Options may be granted under the Plan for no consideration. Options granted under the Plan carry no dividend or voting rights. When exercisable, shares allotted pursuant to the conversion of rights or the exercise of options will be allotted following receipt of relevant documentation and payments will rank equally with all other shares.

As incentive securities granted to employees and directors are considered to represent the value of the services received over the vesting period of the incentive securities, the assessed value of the incentive securities and are recognised and expensed over the vesting period. Incentive securities vesting during the period of issue are fully expensed under the accounting standards. There were no new incentive securities issued during the period.

Invex Therapeutics Ltd
Half Year Report 31 December 2021

NOTES TO THE FINANCIAL STATEMENTS

For the half year ended 31 December 2021

NOTE 5: TRADE AND OTHER PAYABLES

	31 December 2021 \$	30 June 2021 \$
Current:		
Trade payables ⁽¹⁾	311,274	11,333
Accruals & other payables ⁽²⁾	654,727	647,281
	966,001	658,614

(1) Current trade payables are non-interest bearing and are normally settled on 30-day terms.

(2) \$627,269 of the balance relates to accrual for services provided by University of Birmingham.

NOTE 6: ISSUED CAPITAL

	Number of Shares	Value \$
Opening balance – 1 July 2021	75,153,848	36,413,432
Issue of share capital	-	-
Closing balance – 31 December 2021	75,153,848	36,413,432

Ordinary shares have the right to receive dividends as declared, and in the event of winding up the Group, to participate in the proceeds from the sale of all surplus assets in proportion to the number of and amounts paid upon shares held.

Ordinary shares entitle their holder to one vote, either in person or by proxy, at a meeting of the Group.

Capital Management

When managing capital, the Board's objective is to ensure the Group continues as a going concern as well as to maximise the returns to shareholders and benefits for other stakeholders. The Board also aims to maintain a capital structure that ensures the lowest cost of capital available to the Company.

The Board reviews the capital structure to take advantage of favourable costs of capital or high returns on assets. As the market is constantly changing, the Board may issue new shares, return capital to shareholders or sell assets to reduce debt.

The Group was not subject to any externally imposed capital requirements during the period.

Invex Therapeutics Ltd
Half Year Report 31 December 2021

NOTES TO THE FINANCIAL STATEMENTS
For the half year ended 31 December 2021

NOTE 7: RESERVES

Nature and Purpose of Reserve

The Share-based payment reserve records the value of options, performance rights and performance shares issued to the Group's directors, employees, and third parties. The value of the amount disclosed during the period reflects the value of options, performance rights and performance shares issued by the Group.

The Foreign currency translation reserve records exchange differences arising on translation of foreign controlled entities.

	31 December 2021	30 June 2021
	\$	\$
Foreign currency translation reserve	(7,849)	(4,684)
Share-based payment reserve	1,811,577	1,546,240
Total Reserves	1,803,728	1,541,556

Options outstanding at 31 December 2021

The following options over ordinary shares of the Company were granted at reporting date:

Grant Date	Expiry Date	Exercise Price	Balance at start of Period (number)	Granted During the Period (number)	Exercised during the Period (number)	Forfeited during the Period (number)	Balance at Period end (number)	Vested and exercisable at Period end (number)
22 Nov 2019	22 Nov 2023	\$0.60	2,200,000	-	-	-	2,200,000	2,200,000
21 Jan 2020	21 Jan 2023	\$1.00	750,000	-	-	-	750,000	750,000
9 April 2020	9 April 2023	\$0.60	60,000	-	-	-	60,000	30,000
20 Oct 2020	20 Oct 2023	\$1.30	400,000	-	-	-	400,000	200,000
18 Nov 2020	18 Nov 2023	\$1.30	800,000	-	-	-	800,000	400,000
8 April 2021	8 April 2024	\$1.10	400,000	-	-	-	400,000	-
Total			4,610,000	-	-	-	4,610,000	3,780,000

Reconciliation of movement in Share-based payment reserve:

	\$
Opening Balance - 1 July 2021	1,546,240
Share-based payment expense in respect to options on issue as at 31 December 2021	265,337
Closing Balance – 31 December 2021	1,811,577

Invex Therapeutics Ltd
Half Year Report 31 December 2021

NOTES TO THE FINANCIAL STATEMENTS

For the half year ended 31 December 2021

NOTE 8: EVENTS OCCURRING AFTER THE REPORTING PERIOD

The impact of the Coronavirus (COVID-19) pandemic is ongoing with a new Omicron variant circulating widely throughout Australia and the rest of world, including the UK during the financial period. It is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation continues to evolve and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

In January 2022, the Company announced that Professor Alexandra Sinclair had entered into an employment agreement with the Company's UK subsidiary, Invex Therapeutics Ltd, effective 1 March 2022. In addition, the Company entered into a new consultancy agreement with Non-Executive Chairman Dr Jason Loveridge, effective 1 February 2022.

There have been, no other matters or circumstances have arisen since the end of the period which significantly affected or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Company in subsequent financial years.

NOTE 9: COMMITMENTS, CONTINGENT LIABILITIES & CONTINGENT ASSETS

The Directors are not aware of any commitments and contingent liabilities that may arise from the Company's operations as at 31 December 2021.


DIRECTORS' DECLARATION

The directors of Invex Therapeutics Ltd declare that:

- (a) the financial statements comprising the condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of financial position, condensed consolidated statement of cash flows, condensed consolidated statement of changes in equity and accompanying notes, are in accordance with the *Corporations Act 2001* and:
 - i. comply with Accounting Standard AASB 134 Interim Financial Reporting, the Corporations Regulations 2001, and other mandatory professional reporting requirements; and
 - ii. give a true and fair view of the Group's financial position as at 31 December 2021
 - iii. and of its performance of the half year ended on that date
- (b) there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

On behalf of the Directors



David McAuliffe
Non-Executive Director
22 February 2022

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Invex Therapeutics Ltd

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Invex Therapeutics Ltd (the Company) and its subsidiary (the Group), which comprises the condensed consolidated statement of financial position as at 31 December 2021, the condensed consolidated statement of profit or loss and other comprehensive income, the condensed consolidated statement of changes in equity and the condensed consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- (i) Giving a true and fair view of the Group's financial position as at 31 December 2021 and of its financial performance for the half-year ended on that date; and
- (ii) Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

Responsibility of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.



Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2021 and its financial performance for the half-year ended on that date and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit (WA) Pty Ltd

BDO
J Prue

Jarrad Prue

Director

Perth, 22 February 2022